Burden and Sleeping Disorders of Family Caregivers of Hemodialysis Patients with Chronic Kidney Disease-End Stage: A Cross-Sectional Study

Abstract: Chronic kidney disease has got a lot of attention and more widely studied despite reached end stage renal failure, patients still live a long life witha fairly good quality of life although the prevalence is increases throughout the year. one of the circumstances in chronic kidney disease is uremia which is a clinical and laboratory syndrome that occurs inorgans. In uremia interference with platelet function, the production ofprostacyclinin blood vesselswould increase, and excessurea levels in blood would be a potential vasodilator and platelet aggregation antagonist. Methods: An analytic observational cross-sectional study. Samples were patients that diagnosed with chronic kidney disease at the Hospital Clinic of Nephrology-Hypertension Prof. Dr.R. D.Kandou Manado in December toFebruary 2014. Criteria included were patients <80 years old and has been diagnosed with chronic kidney disease in this case had done a physical examination and investigations by doctors, using medical record of urea-creatinine and also a complete blood countand platelet aggregation in Prokita Laboratory Manado. Forstatistical analysisusedShapiro-Wilk testalsoPearsonCorrelationstest. Result: There were 20 patients with chronic kidney disease sampled in this study. It was found that there is a relationship between of urea-creatinine and aggregation results in trace ADP5(P=0.004) while the value ADP10 no significant correlation(P =0.399). Conclusion: In chronic kidney disease patients, urea-creatininewiththe value of platelet aggregation intrace ADP5had a relation ship while intrace ADP10 had not a relationship. Keywords: Chronic kidney disease, platelet aggregation.

Download Full-text

Harmonizing Formula Prescription Patterns for Chronic Kidney Disease: A Population-Based Cross-Sectional Study

10.21203/rs.3.rs-20650/v1 ◽

2020 ◽

Author(s):

Hung-Lung Lin ◽

Ming-Yen Lin ◽

Cheng-Hsun Tasi ◽

Yi-Hsiu Wang ◽

Chung-Jen Chen ◽

...

Keyword(s):

Chronic Kidney Disease ◽

Kidney Disease ◽

Patient Characteristics ◽

Target Population ◽

Population Based ◽

Cross Sectional Study ◽

Sectional Study ◽

Cross Sectional ◽

Stage Renal Disease ◽

End Stage

Abstract Background Harmonizing formulas have been demonstrated to be associated with reduced risk of end-stage renal disease in patients with chronic kidney disease (CKD). However, the target population and indications of harmonizing formulas in CKD remain unknown. Methods We conducted a population-based cross-sectional study to explore factors associated with harmonizing formulas prescription. Patients who had been prescribed harmonizing formulas after CKD diagnosis were defined as the using harmonizing formulas group. Disease diagnoses for harmonizing formula prescriptions and patient characteristics related to the prescriptions were collected. Results In total, 24,971 patients were enrolled in this analysis, and 5,237 (21%) patients were prescribed harmonizing formulas after CKD diagnosis. The three most frequent systematic diseases and related health problems for which harmonizing formula prescriptions were issued in CKD were symptoms, signs, and ill-defined conditions (24.5%), diseases of the digestive system, (20.67%), and diseases of the musculoskeletal system (12.9%). Higher likelihoods of harmonizing formula prescriptions were associated with young age (adjusted odds ratio: 0.98, 95% confidence interval: 0.97–0.98), female sex (1.79, 1.68–1.91), no diabetes (1.20, 1.06–1.35), no hypertension (1.38, 1.26–1.50), no cerebrovascular disease (1.34, 1.14–1.56), less disease severity (0.86, 0.83–0.89), using nonsteroidal anti-inflammatory drugs (NSAIDs) (1.65, 1.54–1.78), and using analgesic drugs other than NSAIDs (1.46, 1.35–1.59). Conclusions Harmonizing formulas are commonly used for treating symptoms of the digestive and musculoskeletal systems in CKD cases. Further research on harmonizing formula effectiveness with regard to particular characteristics of CKD patients is warranted.

Download Full-text

Comparison of health literacy profile of patients with end-stage kidney disease on dialysis versus non-dialysis chronic kidney disease and the influencing factors: a cross-sectional study

BMJ Open ◽

10.1136/bmjopen-2020-041404 ◽

2020 ◽

Vol 10 (10) ◽

pp. e041404

Author(s):

Karumathil Murali ◽

Judy Mullan ◽

Steven Roodenrys ◽

Maureen Lonergan

Keyword(s):

Chronic Kidney Disease ◽

Health Literacy ◽

Kidney Disease ◽

Cross Sectional Study ◽

Health Providers ◽

Sectional Study ◽

End Stage Kidney Disease ◽

Cross Sectional ◽

End Stage ◽

The Impact

ObjectivesLower health literacy (HL) is associated with poor outcomes in patients with kidney disease. Since HL matches the patient’s competencies with the complexities of the care package, the level of HL sufficient in earlier stages of chronic kidney disease (CKD) may be inadequate for patients with end-stage kidney disease (ESKD) on dialysis. We aimed to analyse the HL profile of patients with ESKD and non-dialysis CKD and examine if there were significant associations with covariates which could be targeted to address HL deficits, thereby improving patient outcomes.Design and settingCross-sectional study of patients with CKD and ESKD from a single Australian health district.MethodsWe assessed the HL profile of 114 patients with CKD and 109 patients with ESKD using a 44-item multidomain Health Literacy Questionnaire (HLQ) and examined its association with demographic factors (age, gender, race), smoking, income, education, comorbidities, carer status, cognitive function and depression. Using multivariable logistic regression models, HL profiles of patients with CKD and ESKD were evaluated after adjusting for covariates.ResultsPatients with ESKD had similar demographics and educational levels compared with patients with CKD. ESKD had significantly higher frequency of vascular disease, cognitive impairment and depression. Patients with ESKD had better HL scores for the social support domain (37.1% vs 19.5% in higher HLQ4 tertile, p=0.004), whereas all other HL domains including engagement with healthcare providers were comparable to CKD. Depression was independently associated with nearly all of the HL domains (HLQ1: OR 2.6, p=0.030; HLQ2: OR 7.9, p=<0.001; HLQ3: OR 7.6, p<0.001; HLQ4: OR 3.5, p=0.010; HLQ5: OR 8.9, p=0.001; HLQ6: OR 3.9, p=0.002; HLQ7: OR 4.8, p=0.001; HLQ8: OR 5.3, p=0.001) and education with HL domains relevant to processing health-related information (HLQ8: OR 2.6, p=0.008; HLQ9: OR 2.5, p=0.006).ConclusionsDespite very frequent interactions with health systems, patients with ESKD on dialysis did not have higher HL in engagement with health providers and most other HL domains, compared with patients with CKD. Strategies promoting patient–provider engagement and managing depression which strongly associates with lower HL may address the impact of HL deficits and favourably modify clinical outcomes in renal patients.

Download Full-text

Left ventricular global longitudinal strain in chronic kidney disease patients with and without renal replacement therapy: A cross-sectional study

Indian Heart Journal ◽

10.1016/j.ihj.2020.11.074 ◽

2020 ◽

Vol 72 ◽

pp. S26

Author(s):

Ramesh Sankaran ◽

S. Ramalakshmi ◽

Manish Babbu Uppupetai Ganeshbabbu ◽

M. Jayakumar ◽

T.R. Muralidharan ◽

...

Keyword(s):

Chronic Kidney Disease ◽

Renal Replacement Therapy ◽

Kidney Disease ◽

Replacement Therapy ◽

Longitudinal Strain ◽

Global Longitudinal Strain ◽

Cross Sectional Study ◽

Left Ventricular ◽

Sectional Study ◽

Cross Sectional

Download Full-text

Gut Microbiome Composition Remains Stable in Individuals with Diabetes-Related Early to Late Stage Chronic Kidney Disease

Biomedicines ◽

10.3390/biomedicines9010019 ◽

2020 ◽

Vol 9 (1) ◽

pp. 19

Author(s):

Ashani Lecamwasam ◽

Tiffanie M. Nelson ◽

Leni Rivera ◽

Elif I. Ekinci ◽

Richard Saffery ◽

...

Keyword(s):

Chronic Kidney Disease ◽

Kidney Disease ◽

Relative Abundance ◽

Cross Sectional Study ◽

Early Event ◽

Sectional Study ◽

Cross Sectional ◽

Microbiome Composition ◽

Stool Samples ◽

Late Stages

(1) Background: Individuals with diabetes and chronic kidney disease display gut dysbiosis when compared to healthy controls. However, it is unknown whether there is a change in dysbiosis across the stages of diabetic chronic kidney disease. We investigated a cross-sectional study of patients with early and late diabetes associated chronic kidney disease to identify possible microbial differences between these two groups and across each of the stages of diabetic chronic kidney disease. (2) Methods: This cross-sectional study recruited 95 adults. DNA extracted from collected stool samples were used for 16S rRNA sequencing to identify the bacterial community in the gut. (3) Results: The phylum Firmicutes was the most abundant and its mean relative abundance was similar in the early and late chronic kidney disease group, 45.99 ± 0.58% and 49.39 ± 0.55%, respectively. The mean relative abundance for family Bacteroidaceae, was also similar in the early and late group, 29.15 ± 2.02% and 29.16 ± 1.70%, respectively. The lower abundance of Prevotellaceae remained similar across both the early 3.87 ± 1.66% and late 3.36 ± 0.98% diabetic chronic kidney disease groups. (4) Conclusions: The data arising from our cohort of individuals with diabetes associated chronic kidney disease show a predominance of phyla Firmicutes and Bacteroidetes. The families Ruminococcaceae and Bacteroidaceae represent the highest abundance, while the beneficial Prevotellaceae family were reduced in abundance. The most interesting observation is that the relative abundance of these gut microbes does not change across the early and late stages of diabetic chronic kidney disease, suggesting that this is an early event in the development of diabetes associated chronic kidney disease. We hypothesise that the dysbiotic microbiome acquired during the early stages of diabetic chronic kidney disease remains relatively stable and is only one of many risk factors that influence progressive kidney dysfunction.

Download Full-text

FGF-23 and Phosphate in Children with Chronic Kidney Disease: A Cross-Sectional Study in Kazakhstan

Medicina ◽

10.3390/medicina57010015 ◽

2020 ◽

Vol 57 (1) ◽

pp. 15

Author(s):

Altynay Balmukhanova ◽

Kairat Kabulbayev ◽

Harika Alpay ◽

Assiya Kanatbayeva ◽

Aigul Balmukhanova

Keyword(s):

Chronic Kidney Disease ◽

Kidney Disease ◽

Fibroblast Growth Factor 23 ◽

Cross Sectional Study ◽

Sectional Study ◽

Cross Sectional ◽

Ckd Stage ◽

Advanced Stages ◽

Fgf 23 ◽

Stage 1

Background and objectives: Chronic kidney disease (CKD) in children is a complex medical and social issue around the world. One of the serious complications is mineral-bone disorder (CKD-MBD) which might determine the prognosis of patients and their quality of life. Fibroblast growth factor 23 (FGF-23) is a phosphaturic hormone which is involved in the pathogenesis of CKD-MBD. The purpose of the study was to determine what comes first in children with CKD: FGF-23 or phosphate. Materials and Methods: This cross-sectional study included 73 children aged 2–18 years with CKD stages 1–5. We measured FGF-23 and other bone markers in blood samples and studied their associations. Results: Early elevations of FGF-23 were identified in children with CKD stage 2 compared with stage 1 (1.6 (1.5–1.8) pmol/L versus 0.65 (0.22–1.08), p = 0.029). There were significant differences between the advanced stages of the disease. FGF-23 correlated with PTH (r = 0.807, p = 0.000) and phosphate (r = 0.473, p = 0.000). Our study revealed that the elevated level of FGF-23 went ahead hyperphosphatemia and elevated PTH. Thus, more than 50% of children with CKD stage 2 had the elevating level of serum FGF-23, and that index became increasing with the disease progression and it achieved 100% at the dialysis stage. The serum phosphate increased more slowly and only 70.6% of children with CKD stage 5 had the increased values. The PTH increase was more dynamic. Conclusions: FGF-23 is an essential biomarker, elevates long before other markers of bone metabolism (phosphate), and might represent a clinical course of disease.

Download Full-text